The Administrative Core is composed of Cancer Center Administration and Senior Leadership of the Sidney Kimmel Comprehensive Cancer Center (SKCCC). The SKCCC Administration's purposes are to facilitate the overall planning, management and organization of the activities of the SKCCC, and to provide the support necessary to achieve and maintain the highest standards of cancer research excellence at the SKCCC. Administration is vital in assuring that the SKCCC achieves its goals and objectives and complies with NCI guidelines for Cancer Center Support Grants (CCSG). These goals are accomplished through an administrative infrastructure that enables streamlined and effective assistance to the Director, Senior Leaders, Program Leaders, Advisory Groups, Core Directors/Managers and general membership. SKCCC Administration provides the centralized management of resources and services required for the SKCCC's research activities, fiscal management and reporting functions. Coordinated activities include: participation in SKCCC governance and decision-making processes; representation of the SKCCC within the institution; oversight and management of CCSG relevant activities, including planning and evaluation oversight of Cores; faculty recruitment support; and management of the membership process and data, space, budgeting and finances, and the CCSG application. SKCCC Senior Leadership is responsible for overall planning and operational activities, administrative and management functions that support SKCCC research, and all scientific Program functions as described in detail throughout this CCSG application. The overall responsibility for planning and operation of research rests with the Director of the SKCCC, William G. Nelson, M.D., Ph.D. Dr. Nelson has carefully assembled a highly cohesive and dynamic Senior Leadership team with a strong commitment to the goals, values and priorities of the SKCCC. The Deputy Director and Associate Directors (ADs) have broad responsibilities and work with the Director to plan scientific direction with particular emphasis on Program interaction and translational research. The Deputy Director and ADs have significant oversight responsibilities for the Research Programs and in research training, education, community programs and outreach. Their collective success is evidenced by new strategic initiatives, evolution of Programs, development of Cores, increased transdisciplinary collaboration along the translational pipeline and, in particular, the impact on the SKCCC catchment area. They are continuously focused on the priorities of the SKCCC, including understanding and addressing cancer disparities. SKCCC leadership includes the Director, Deputy Director (Elizabeth M. Jaffee, M.D.), an AD for Clinical Research (Michael A. Carducci, M.D.), an AD for Population Sciences (John D. Groopman, Ph.D.), an AD for Shared Resources (Robert A. Casero, Ph.D.), an AD for Laboratory Research (Kenneth Kinzler, Ph.D.), an AD for Research Training and Education (Ben Park, M.D., Ph.D.), and an AD for Administration (Rosalie W ollett).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006973-54
Application #
9278330
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-05-01
Budget End
2018-04-30
Support Year
54
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663
Boudadi, Karim; Suzman, Daniel L; Anagnostou, Valsamo et al. (2018) Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget 9:28561-28571
Dean, Lorraine T; Gehlert, Sarah; Neuhouser, Marian L et al. (2018) Social factors matter in cancer risk and survivorship. Cancer Causes Control 29:611-618
Yuan, Ming; Da Silva, Ana Cristina A L; Arnold, Antje et al. (2018) MicroRNA (miR) 125b regulates cell growth and invasion in pediatric low grade glioma. Sci Rep 8:12506
Jacobs, Michael A; Macura, Katarzyna J; Zaheer, Atif et al. (2018) Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. Acad Radiol 25:1405-1414
Annesley, Colleen E; Rabik, Cara; Duffield, Amy S et al. (2018) Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice. Oncotarget 9:35313-35326
Liu, Tao; Ivaturi, Vijay; Sabato, Philip et al. (2018) Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship. Clin Transl Sci 11:435-443

Showing the most recent 10 out of 2393 publications